Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reduvo updates April 14 2022 MD&A

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Apr 24, 2022 8:44pm

109 Views

Post# 34627819

RE:RE:RE:Reduvo updates April 14 2022 MD&A

I just checked it is the same at 18. You need to sort it by the date of submission acceptance. You can look at the approved applications also. With similar applications took about 10 months from the date of submission acceptance (not the date of submission). We already past that. Reduvo was submitted by Tbp Dec 2020 accepted by HC on may 2021. It will complete a year by end of next week. Latest we know is the ma&d I shared last week.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024